Neoprofen Solution
NDC Package 55292-122-52
Package Information
Neoprofen (ibuprofen lysine) solution is neoProfen is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. This formulation utilizes a solution delivery system. Marketed by Recordati Rare Diseases Inc., this product is identified by NDC 55292-122 and is authorized under FDA application NDA021903.
Identification & Billing
- RxCUI: 1747294 - ibuprofen lysine 10 MG/ML in 2 ML Injection
- RxCUI: 1747294 - 2 ML ibuprofen 10 MG/ML Injection
- RxCUI: 1747294 - ibuprofen 10 MG/ML (as ibuprofen lysine 17.1 MG/ML) per 2 ML Injection
- RxCUI: 637197 - NeoProfen 10 MG/ML in 2 ML Injection
- RxCUI: 637197 - 2 ML ibuprofen 10 MG/ML Injection [Neoprofen]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 55292 - Recordati Rare Diseases Inc.
- 55292-122 - Neoprofen
- 55292-122-52 - 3 VIAL in 1 CARTON / 2 mL in 1 VIAL
- 55292-122 - Neoprofen
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55292-122-52 identifies a specific commercial package of 3 vial in 1 carton / 2 ml in 1 vial of Neoprofen, a human prescription drug labeled by Recordati Rare Diseases Inc.. This solution is formulated for intravenous use and contains ibuprofen lysine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Recordati Rare Diseases Inc. on April 13, 2006. The current certification is valid through December 31, 2026.
How is this Recordati Rare Diseases Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55292012252. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.